Company Overview and Regulatory Context

Valiant Organics Limited submitted an Investor Presentation to BSE Ltd and National Stock Exchange of India Limited on November 19, 2026, pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015. The presentation covers financial results for the quarter and half year ended September 30, 2026. The company is incorporated in 1984 and is a manufacturer of specialty chemicals used in agrochemicals, pharmaceuticals, dyes, pigments, and veterinary medications. It has 6 manufacturing units across 5 locations with a total production capacity of 80,800 TPA and employs 900+ people. Market capitalization was INR 12,792.19 Mn as of September 30, 2026.

Key Financial Performance Highlights (Consolidated)

Q2-FY27 Performance:

  • Revenue from Operations: INR 3,042 Mn (93.4% YoY growth, 31.4% QoQ growth)
  • Total Expenses: INR 2,652 Mn (94.9% YoY growth, 39.7% QoQ growth)
  • Operating EBITDA: INR 390 Mn (84.0% YoY growth, -6.3% QoQ decline)
  • Operating EBITDA Margin: 12.82% (66 bps decline YoY, 515 bps decline QoQ)
  • Profit After Tax: INR 173 Mn (203.5% YoY growth, -41.0% QoQ decline)
  • PAT Margin: 5.69% (207 bps improvement YoY, 697 bps decline QoQ)
  • Basic/Diluted EPS: INR 6.12 per share
  • Other Income: INR 11 Mn
  • Depreciation: INR 103 Mn
  • Finance Cost: INR 52 Mn
  • Share of Profit from Associates: INR 2 Mn
  • Tax: INR 75 Mn

H1-FY27 Performance:

  • Revenue from Operations: INR 5,358 Mn (48.1% YoY growth)
  • Total Expenses: INR 4,552 Mn (44.1% YoY growth)
  • Operating EBITDA: INR 806 Mn (75.6% YoY growth)
  • Operating EBITDA Margin: 15.04% (235 bps improvement YoY)
  • Profit After Tax: INR 466 Mn (235.3% YoY growth)
  • PAT Margin: 8.70% (486 bps improvement YoY)
  • Basic/Diluted EPS: INR 16.22 per share
  • Other Income: INR 44 Mn
  • Depreciation: INR 205 Mn
  • Finance Cost: INR 103 Mn
  • Share of Profit from Associates: INR 74 Mn
  • Tax: INR 150 Mn

Operational Highlights

  • Sales volumes increased 28% quarter-on-quarter and 43% year-on-year in Q2-FY27
  • Hydrogenation volumes grew 27% QoQ, with revenue rising 37% to INR 1,744 Mn (56% of quarterly revenue)
  • Ammonolysis volumes increased 60% QoQ across Vapi and Tarapur, with revenue up 50% to INR 715 Mn
  • Chlorination volumes grew 4% QoQ, but revenue declined to INR 438 Mn from INR 452 Mn in Q1-FY27 due to lower chlorophenol realizations and higher phenol costs
  • Revenue from acetylation and sulphonation increased 44% QoQ to INR 203 Mn
  • H1-FY27 capital expenditure was INR 263 Mn, primarily directed towards Sarigam and the two Jhagadia units

Standalone Financial Performance

Q2-FY27 Standalone:

  • Revenue from Operations: INR 3,042 Mn (93.5% YoY growth, 31.4% QoQ growth)
  • PAT: INR 172 Mn (207.1% YoY growth, -21.1% QoQ decline)
  • PAT Margin: 5.65% (209 bps improvement YoY, 377 bps decline QoQ)
  • Basic/Diluted EPS: INR 6.12 per share

H1-FY27 Standalone:

  • Revenue from Operations: INR 5,358 Mn (48.2% YoY growth)
  • PAT: INR 390 Mn (195.5% YoY growth)
  • PAT Margin: 7.28% (363 bps improvement YoY)
  • Basic/Diluted EPS: INR 13.91 per share

Historical Financial Overview

Consolidated Historical Performance:

  • FY24: Revenue INR 7,231 Mn, EBITDA INR 382 Mn (5.28% margin), PAT INR (84) Mn (-1.16% margin)
  • FY25: Revenue INR 7,188 Mn, EBITDA INR 537 Mn (7.47% margin), PAT INR (34) Mn (-0.47% margin)
  • FY26: Revenue INR 7,388 Mn, EBITDA INR 882 Mn (11.94% margin), PAT INR 332 Mn (4.49% margin)
  • H1-FY27: Revenue INR 5,358 Mn, EBITDA INR 806 Mn (15.04% margin), PAT INR 466 Mn (8.70% margin)

Balance Sheet Position (Consolidated as of H1-FY27):

  • Total Equity: INR 8,063 Mn (including Equity Share Capital of INR 280 Mn)
  • Non-Current Liabilities: INR 1,426 Mn (Borrowings: INR 644 Mn, Lease Liabilities: INR 23 Mn, Deferred Tax Liabilities: INR 554 Mn)
  • Current Liabilities: INR 3,863 Mn (Borrowings: INR 1,921 Mn, Trade Payables: INR 1,539 Mn)
  • Total Assets: INR 13,352 Mn

Share Data and Ownership

  • Face Value: INR 10.00
  • Market Price as of September 30, 2026: INR 456.30
  • 52 Week High/Low: INR 467.15/195.20
  • Equity Shares Outstanding: 28.03 Mn
  • 1 Year Average Trading Volume: 66,170 shares

Additional Information

The presentation includes standard disclaimer language noting that it contains forward-looking statements based on management's current beliefs and assumptions, and that past performance is not necessarily indicative of future results. The document also notes that Valiant Laboratories Limited ceased to be a step-down subsidiary and became an associate company effective October 4, 2023, making previous periods' consolidated financials not comparable.

Investor relations contact information is provided for Valorem Advisors, the company's investor relations representatives.